Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

Establishment of a Shigella sonnei human challenge model in Thailand.

Bodhidatta L, Pitisuttithum P, Chamnanchanant S, Chang KT, Islam D, Bussaratid V, Venkatesan MM, Hale TL, Mason CJ.

Vaccine. 2012 Nov 19;30(49):7040-5. doi: 10.1016/j.vaccine.2012.09.061. Epub 2012 Oct 12.

2.

Comparative evaluation of the antibody in lymphocyte supernatant (ALS) and enzyme-linked immunospot (ELISPOT) assays for measuring mucosal immune responses to Shigella antigens.

Feller AJ, McKenzie R, Taylor DN, Woods CC, Grahek SL, Islam D, Venkatesan MM, Hale TL, Bourgeois AL.

Vaccine. 2011 Nov 3;29(47):8487-9. doi: 10.1016/j.vaccine.2011.09.030. Epub 2011 Sep 20.

3.

Shigella sonnei vaccine candidates WRSs2 and WRSs3 are as immunogenic as WRSS1, a clinically tested vaccine candidate, in a primate model of infection.

Barnoy S, Baqar S, Kaminski RW, Collins T, Nemelka K, Hale TL, Ranallo RT, Venkatesan MM.

Vaccine. 2011 Aug 26;29(37):6371-8. doi: 10.1016/j.vaccine.2011.04.115. Epub 2011 May 17.

PMID:
21596086
4.

Shigella.

Hale TL, Keusch GT.

In: Baron S, editor. Medical Microbiology. 4th edition. Galveston (TX): University of Texas Medical Branch at Galveston; 1996. Chapter 22.

5.

Safety, dose, immunogenicity, and transmissibility of an oral live attenuated Shigella flexneri 2a vaccine candidate (SC602) among healthy adults and school children in Matlab, Bangladesh.

Rahman KM, Arifeen SE, Zaman K, Rahman M, Raqib R, Yunus M, Begum N, Islam MS, Sohel BM, Rahman M, Venkatesan M, Hale TL, Isenbarger DW, Sansonetti PJ, Black RE, Baqui AH.

Vaccine. 2011 Feb 1;29(6):1347-54. doi: 10.1016/j.vaccine.2010.10.035. Epub 2010 Oct 30.

PMID:
21040694
6.

Vaccination of children in low-resource countries against Shigella is unlikely to present an undue risk of reactive arthritis.

Gaston JS, Inman RD, Ryan ET, Venkatesan MM, Barry EM, Hale TL, Bourgeois AL, Walker RI.

Vaccine. 2009 Sep 4;27(40):5432-4. doi: 10.1016/j.vaccine.2009.06.107. Epub 2009 Jul 28.

PMID:
19643213
7.

Safety and immunogenicity of WRSd1, a live attenuated Shigella dysenteriae type 1 vaccine candidate.

McKenzie R, Venkatesan MM, Wolf MK, Islam D, Grahek S, Jones AM, Bloom A, Taylor DN, Hale TL, Bourgeois AL.

Vaccine. 2008 Jun 19;26(26):3291-6. doi: 10.1016/j.vaccine.2008.03.079. Epub 2008 Apr 16.

PMID:
18468742
8.

Community-based safety, immunogenicity, and transmissibility study of the Shigella sonnei WRSS1 vaccine in Israeli volunteers.

Orr N, Katz DE, Atsmon J, Radu P, Yavzori M, Halperin T, Sela T, Kayouf R, Klein Z, Ambar R, Cohen D, Wolf MK, Venkatesan MM, Hale TL.

Infect Immun. 2005 Dec;73(12):8027-32.

9.

Ultrasound measured renal length versus low dose CT volume in predicting single kidney glomerular filtration rate.

Widjaja E, Oxtoby JW, Hale TL, Jones PW, Harden PN, McCall IW.

Br J Radiol. 2004 Sep;77(921):759-64.

PMID:
15447962
10.

Detection of Shigella by a PCR assay targeting the ipaH gene suggests increased prevalence of shigellosis in Nha Trang, Vietnam.

Vu DT, Sethabutr O, Von Seidlein L, Tran VT, Do GC, Bui TC, Le HT, Lee H, Houng HS, Hale TL, Clemens JD, Mason C, Dang DT.

J Clin Microbiol. 2004 May;42(5):2031-5.

11.

Two studies evaluating the safety and immunogenicity of a live, attenuated Shigella flexneri 2a vaccine (SC602) and excretion of vaccine organisms in North American volunteers.

Katz DE, Coster TS, Wolf MK, Trespalacios FC, Cohen D, Robins G, Hartman AB, Venkatesan MM, Taylor DN, Hale TL.

Infect Immun. 2004 Feb;72(2):923-30.

12.

Construction, characterization, and animal testing of WRSd1, a Shigella dysenteriae 1 vaccine.

Venkatesan MM, Hartman AB, Newland JW, Ivanova VS, Hale TL, McDonough M, Butterton J.

Infect Immun. 2002 Jun;70(6):2950-8.

13.

Phase I evaluation of delta virG Shigella sonnei live, attenuated, oral vaccine strain WRSS1 in healthy adults.

Kotloff KL, Taylor DN, Sztein MB, Wasserman SS, Losonsky GA, Nataro JP, Venkatesan M, Hartman A, Picking WD, Katz DE, Campbell JD, Levine MM, Hale TL.

Infect Immun. 2002 Apr;70(4):2016-21.

14.

Safety and immunogenicity of a proteosome-Shigella flexneri 2a lipopolysaccharide vaccine administered intranasally to healthy adults.

Fries LF, Montemarano AD, Mallett CP, Taylor DN, Hale TL, Lowell GH.

Infect Immun. 2001 Jul;69(7):4545-53.

15.

Novel self-sampling culture method to monitor excretion of live, oral Shigella flexneri 2a vaccine SC602 during a community-based phase 1 trial.

Teska JD, Coster T, Byrne WR, Colbert JR, Taylor D, Venkatesan M, Hale TL.

J Lab Clin Med. 1999 Aug;134(2):141-6.

PMID:
10444027
16.

Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602.

Coster TS, Hoge CW, VanDeVerg LL, Hartman AB, Oaks EV, Venkatesan MM, Cohen D, Robin G, Fontaine-Thompson A, Sansonetti PJ, Hale TL.

Infect Immun. 1999 Jul;67(7):3437-43.

17.

Transcutaneous immunization with cholera toxin protects mice against lethal mucosal toxin challenge.

Glenn GM, Scharton-Kersten T, Vassell R, Mallett CP, Hale TL, Alving CR.

J Immunol. 1998 Oct 1;161(7):3211-4.

18.

Double-blind vaccine-controlled randomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults.

Cohen D, Ashkenazi S, Green MS, Gdalevich M, Robin G, Slepon R, Yavzori M, Orr N, Block C, Ashkenazi I, Shemer J, Taylor DN, Hale TL, Sadoff JC, Pavliakova D, Schneerson R, Robbins JB.

Lancet. 1997 Jan 18;349(9046):155-9.

PMID:
9111538
19.

A modified Shigella volunteer challenge model in which the inoculum is administered with bicarbonate buffer: clinical experience and implications for Shigella infectivity.

Kotloff KL, Nataro JP, Losonsky GA, Wasserman SS, Hale TL, Taylor DN, Sadoff JC, Levine MM.

Vaccine. 1995 Nov;13(16):1488-94.

PMID:
8578831
20.
21.
22.
23.

Antibody and cytokine responses in a mouse pulmonary model of Shigella flexneri serotype 2a infection.

van de Verg LL, Mallett CP, Collins HH, Larsen T, Hammack C, Hale TL.

Infect Immun. 1995 May;63(5):1947-54.

24.

Evaluation of the safety, immunogenicity, and efficacy in healthy adults of four doses of live oral hybrid Escherichia coli-Shigella flexneri 2a vaccine strain EcSf2a-2.

Kotloff KL, Losonsky GA, Nataro JP, Wasserman SS, Hale TL, Taylor DN, Newland JW, Sadoff JC, Formal SB, Levine MM.

Vaccine. 1995 Apr;13(5):495-502.

PMID:
7639017
25.

Evaluation of Shigella vaccine safety and efficacy in an intranasally challenged mouse model.

Mallett CP, VanDeVerg L, Collins HH, Hale TL.

Vaccine. 1993;11(2):190-6.

PMID:
8438617
26.

Safety, immunogenicity, and efficacy in monkeys and humans of invasive Escherichia coli K-12 hybrid vaccine candidates expressing Shigella flexneri 2a somatic antigen.

Kotloff KL, Herrington DA, Hale TL, Newland JW, Van De Verg L, Cogan JP, Snoy PJ, Sadoff JC, Formal SB, Levine MM.

Infect Immun. 1992 Jun;60(6):2218-24.

28.

Pathogenesis and immunology in shigellosis: applications for vaccine development.

Hale TL, Keren DF.

Curr Top Microbiol Immunol. 1992;180:117-37. Review. No abstract available.

PMID:
1380415
29.

Genetic basis of virulence in Shigella species.

Hale TL.

Microbiol Rev. 1991 Jun;55(2):206-24. Review.

30.

Virulence phenotype and genetic characteristics of the T32-ISTRATI Shigella flexneri 2a vaccine strain.

Venkatesan M, Fernandez-Prada C, Buysse JM, Formal SB, Hale TL.

Vaccine. 1991 May;9(5):358-63.

PMID:
1872021
31.

Hybrid vaccines using Escherichia coli as an antigen carrier.

Hale TL.

Res Microbiol. 1990 Sep-Oct;141(7-8):913-9. No abstract available.

PMID:
2101482
32.
33.
34.
35.

Shigella vaccines.

Formal SB, Hale TL, Kapfer C.

Rev Infect Dis. 1989 May-Jun;11 Suppl 3:S547-51. Review.

PMID:
2669098
36.
37.

Intracellular spread of Shigella flexneri associated with the kcpA locus and a 140-kilodalton protein.

Pál T, Newland JW, Tall BD, Formal SB, Hale TL.

Infect Immun. 1989 Feb;57(2):477-86.

38.

Oral shigella vaccines.

Hale TL, Formal SB.

Curr Top Microbiol Immunol. 1989;146:205-11. Review. No abstract available.

PMID:
2659269
39.

Recurrent shigellosis complicating human immunodeficiency virus infection: failure of pre-existing antibodies to confer protection.

Blaser MJ, Hale TL, Formal SB.

Am J Med. 1989 Jan;86(1):105-7. No abstract available.

PMID:
2642653
40.

Pathogenesis, genetics of virulence, and immunity in Shigellosis.

Formal SB, Kapfer C, Hale TL.

Kansenshogaku Zasshi. 1988 Mar;62 Suppl:329-42. Review. No abstract available.

PMID:
3138359
41.

Association of pathogens with the intestinal mucosa and the design of vaccines.

Formal SB, Hale TL, Kapfer C.

Monogr Allergy. 1988;24:46-50. No abstract available.

PMID:
3283533
42.

Local and systemic antibody responses to Shigella infection in rhesus monkeys.

Dinari G, Hale TL, Austin SW, Formal SB.

J Infect Dis. 1987 May;155(5):1065-9. No abstract available.

PMID:
3549918
43.

Pathogenesis of Shigella infections.

Hale TL, Formal SB.

Pathol Immunopathol Res. 1987;6(2):117-27. Review. No abstract available.

PMID:
3321018
44.

Genetics of virulence in Shigella.

Hale TL, Formal SB.

Microb Pathog. 1986 Dec;1(6):511-8. Review. No abstract available.

PMID:
3334157
45.
46.

Invasion of epithelial cells by shigellae.

Hale TL.

Ann Inst Pasteur Microbiol (1985). 1986 May-Jun;137A(3):311-4. No abstract available.

PMID:
3322174
47.
50.

Cloning of plasmid DNA sequences involved in invasion of HeLa cells by Shigella flexneri.

Maurelli AT, Baudry B, d'Hauteville H, Hale TL, Sansonetti PJ.

Infect Immun. 1985 Jul;49(1):164-71.

Supplemental Content

Support Center